2016-05-06 15:20

 

Wei Zexi event: India medicine has not been licensed domestic drug prices high

 

[straight news network Beijing, May 6 news] (daily financial news) Wei Zexi events continued fermentation, Baidu, Armed Police Corps in Beijing Second Hospital, Putian system, biological immune therapy, cancer treatment and generic drugs and other topics is pushed to the cusp.
In this regard, the industry has the view that the Wei Zexi event has the potential to change the status quo of China's private medical industry. In the long run, this change may be able to achieve. But at this stage, it is necessary to pay attention to, the 2015 China cancer statistics, is expected to add about a new cancer cases, cancer deaths or more than. In the face of this situation, our country's cancer treatment and the status quo of the pharmaceutical industry is worthy of our attention.
Young Wei Zexi left to let the imitation pharmaceutical problems in the public eye. Wei Zexi to eat a kind of medicine, in China's Hong Kong buy is 44000 yuan a month or 40 days, he can not afford to eat, but in India to buy as long as 5000 yuan, but do not allow entry.
This drug is cancer patients are very dependent on the India generic drugs. Because the patent compulsory license system, India became the world pharmacy and drug price cheap, efficacy claims and the original drug research is almost the same. "Domestic generic drugs, due to pricing mechanisms and environmental reasons, the price is more expensive than in India." China Pharmaceutical Industry Information Center Chief Consultant Huang Donglin said.
In addition, some domestic generic drug also has the problem of low efficacy. However, with the development and improvement of the state of the quality and efficacy of the generic evaluation of generic evaluation policy, the pharmaceutical industry has gradually ushered in the adjustment.
India is a great advantage of generic drugs
Generic drug is a generic drug that is the same as the original one in terms of dosage, effect and indication. Generic drugs and the original research medicine contain the same active ingredients, with a biological equivalent, and in dosage forms, specifications and drug delivery methods are also consistent with the original research.
The original research drug R & D often requires more than ten years of time and a huge capital investment, research and development of new drugs cost passed on to prices. The original drug patent protection period is generally 20 years, after the expiration of patent protection, pharmaceutical companies can be copied. During the patent protection period, the price of the original research drugs are expensive, the average price of generic drugs only 20% to 40% of the original research drug, the difference between the individual drugs.
And India's unique patent compulsory license allows it to be able to make a lot of new drugs. Indian patent law, the compulsory license application to the public for the patented invention reasonable needs unmet, or the public not to reasonable can pay the price gets the patented invention, or the patent invention not used within the territory of India of.
Indian patent law amendment case (2005), the new increase of compulsory license of the relevant provisions of the applicable scope, the terms of the compulsory licensing under the Indian generics can be exported to non related production capacity of regions and countries. Some media reports, more than 60% of India's generic drugs exported to the United States and Europe, Japan and other developed countries, including the U.S. market, nearly 40% of generic drugs from India. Many multinational pharmaceutical giant sued the India pharmaceutical companies, but the end of the infringement.
In recent years, many of China's multinational purchasing drugs accused the sales of counterfeit drugs, these drugs are mostly in India after the approval of the legitimate drug, but without obtaining the import licenses of the relevant departments of China.
Board of directors of the Xin Houdong China Pharmaceutical Group Company in India once told the media said that China as world powers have an obligation to protect intellectual property rights, to India's generics this clear violation of medical and pharmaceutical intellectual property products cannot be imported; secondly the drugs grinds the medicine originally many has been in China for patent registration, drug, belong to the enterprise has the drug in the sale of Chinese, want to see generics and sales; in addition, for more than part of period of patent protection of drugs, pharmaceutical enterprises in China has in generics, there is no need to re imported from India. These are the reasons in the Chinese ban India generics.
Domestic imitation pharmaceutical companies welcome reshuffle
In fact, domestic generics also have a very large market size. Data show that over the past 10 years Chinese generic drug market is developing rapidly, the scale of nearly 5000 million yuan, the generic drugs in prescriptions accounted for up to 95%. Another data show that from the beginning of 2012 to the end of 5 2016 years, the world has as many as 631 patent drugs expire, which gives a huge market for generic drugs.
However, compared with India, the same generic imitation of domestic patients are more willing to choose India products. "India's cheap ah, pharmaceutical competition is very fierce. In addition, the Indian in the international context do better, can reach the standards of the United States. And the domestic generic drugs, due to the pricing mechanism and the reasons for the environment, the price is more expensive." China Pharmaceutical Industry Information Center Chief Consultant Huang Donglin said.
There is a gap between the quality of domestic generic drugs, the efficacy and the original drug." Beijing Ding Chen medicine management consulting center Shi Lichen said.
"In 2002 to the first half of 2006, the domestic generic drug approval number is the potential of the blowout, China in a short period of time become the big country generics, but generics are not power, low level of imitation gathers together the phenomenon is serious, many drug approval number of dozens or even hundreds of, the pharmaceutical enterprises between the vicious competition. At the same time, a large number of listed companies have not been approved for the consistency of the consistency of the evaluation of the original study, the general quality of the poor, the problem of weak efficacy." China Securities research report pointed out.
However, with the development of relevant policies, the domestic generic pharmaceutical industry is about to usher in a reshuffle. Recently, the State Food and Drug Administration posting a series of deployment of generic consistency evaluation matters, in the draft regulations prior to the implementation of the classification of chemicals registration of new approved the listing of generics, including domestic generics, import generic drugs and drug estate varieties shall be carried out by evaluation and will complete the consistency evaluation time is set at the end of 2018.
"China has more than 4700 pharmaceutical companies, there are less than 1000 R & D capabilities. Now the chemical generics may only be 1/3 to 1/2 to be able to pass the consistency evaluation. This is the industry reshuffle." Shi Lichen said.
(original title: Wei Zexi event: India medicine has not been licensed domestic drug prices high)
Editor: Xiao Shen
Interpretation of the news hot spots, showing sensitive events, more exclusive analysis, in the "things" WeChat, scan two-dimensional code free reading.